New therapeutic targets to treat non-alcoholic fatty liver
Faculdade de Farmácia da Universidade de Lisboa, Portugal
Non-alcoholic fatty liver disease is the most common chronic liver disease, affecting one third of the population. Moreover, the increase in diabetes and obesity around the world is raising the risk of people developing the disease.
However, there is no reliable diagnosis or treatment for this disorder. One of the unexplored therapeutic targets is the RIPK protein, which affects cell death and whose role in liver inflammation is unknown.
The project focuses on RIPK to understand the metabolic disturbances that contribute to inflammation and the death of liver cells, with the aim of preventing the disease and finding drugs that can influence its course.
RIPK3 biology and targeting in metabolic liver disease